GGrantIndex
Sort

48,018 grants matching immunotherapy

Enhancing efficacy of vaccines for substance abuse through polymer-assisted delivery of immunomodulators

$439,201
Marco Pravetoni · Hennepin Healthcare Research Institute · R01 · FY2016 · DA

Optimization of RORgamma-specific agonists as immune activators for a new immunotherapy approach for cancer

$439,200
Patrick Robert Griffin · Scripps Florida · R01 · FY2017 · CA

Optimization of RORgamma-specific agonists as immune activators for a new immunotherapy approach for cancer

$439,200
Patrick Robert Griffin · Scripps Florida · R01 · FY2016 · CA

Optimization of RORgamma-specific agonists as immune activators for a new immunotherapy approach for cancer

$439,200
Patrick Robert Griffin · Scripps Florida · R01 · FY2018 · CA

Targeting TERT in Melanoma

$439,183
Jessie Villanueva · Wistar Institute · R01 · FY2017 · CA

Boosting Antitumor Immunity by Blocking Both Tumor and Adipose DDR1

$439,100
Rong Li · George Washington University · R01 · FY2024 · CA

Tackling Treg mediated resistance to radiation and anti-PDL1 in HNSCCs

$439,092
Sana D Karam · University Of Colorado Denver · R01 · FY2021 · DE

Tackling Treg mediated resistance to radiation and anti-PDL1 in HNSCCs

$439,092
Sana D Karam · University Of Colorado Denver · R01 · FY2020 · DE

Tackling Treg mediated resistance to radiation and anti-PDL1 in HNSCCs

$439,092
Sana D Karam · University Of Colorado Denver · R01 · FY2019 · DE

Tackling Treg mediated resistance to radiation and anti-PDL1 in HNSCCs

$439,092
Sana D Karam · University Of Colorado Denver · R01 · FY2023 · DE

Dendritic Cell-Based Immunotherapy for HIV Infection

$439,045
University Of Pittsburgh At Pittsburgh · P01 · FY2003 · AI

Data Management and Analysis Core

$439,035
Aris Floratos · Columbia University Health Sciences · U19 · FY2020 · AI

Using Nonclassical Estrogen Signaling to Prevent Melanoma

$438,974
Todd W Ridky · University Of Pennsylvania · R01 · FY2021 · CA

Molecular Mechanisms for Antiviral Signal Activation by MDA5 and RIG-I

$438,958
Sun Hur · Boston Children'S Hospital · R01 · FY2014 · AI

BET degraders for improving colorectal cancer therapy

$438,915
Lin Zhang · University Of Southern California · R01 · FY2025 · CA

American Trial Using Tranexamic Acid in Thrombocytopenia (A-TREAT) - DCC

$438,909
Susanne May · University Of Washington · U01 · FY2019 · HL

Basophil phenotype & activation in peanut allergy and oral Immunotherapy

$438,843
Stephen J Galli · Stanford University · U19 · FY2015 · AI

DNA damage response and cancer immunity

$438,804
Christopher J. Bakkenist · University Of Pittsburgh At Pittsburgh · R01 · FY2024 · CA

Therapy with fecal microbiota transplantation and immune checkpoint blockade for solid tumors

$438,800
Hassane M Zarour · University Of Pittsburgh At Pittsburgh · U01 · FY2024 · CA

Repertoire selection of AQP4-specific T cells that cause CNS autoimmunedisease

$438,798
Scott S Zamvil · University Of California, San Francisco · R01 · FY2021 · AI

Treatment of RSV Bronchiolitis with NSAIDs

$438,794
Jorge C Blanco · Virion Systems, Inc. · R43 · FY2006 · AI

Cell and Gene Therapy, Clinical Manufacture and Monitoring Core

$438,766
Antoni Ribas · California Institute Of Technology · P01 · FY2013 · CA

Treatment/Type 1 Diabetes/hGAD65 Altered Peptide Ligand

$438,750
Benaroya Research Inst At Virginia Mason · R21 · FY2003 · DK

Development of mAb therapeutics against biothreat and emerging diease agents

$438,736
Thomas Briese · Columbia University Health Sciences · U54 · FY2009 · AI

Image-guided Trp-IDO/TDO-Kyn-AHR pathway inhibition, combined with immunotherapy

$438,732
Taha Merghoub · Weill Medical Coll Of Cornell Univ · R01 · FY2024 · CA